

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

10177-142-999

09/891,715

APPLICANT

Mueller et al.

FILING DATE

June 26, 2001

GROUP

1617


## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
cm	AA	3,773,034	11/20/73	Burns <i>et al.</i>			
	AB	3,952,742	04/27/76	Taylor			
	AC	4,296,100	10/20/81	Franco			
	AD	4,531,936	07/30/85	Gordon			
	AE	4,657,536	04/14/87	Dorman			
	AF	4,770,653	09/13/88	Shturman			
	AG	4,911,148	03/27/90	Sosnowski <i>et al.</i>			
	AH	4,946,442	08/07/90	Sanagi			
	AI	4,994,033	02/19/91	Shockey <i>et al.</i>			
	AJ	5,061,223	10/29/91	Yock			
	AK	5,185,004	02/09/93	Lashinski			
	AL	5,203,772	04/20/93	Hammerslag <i>et al.</i>			
	AM	5,244,460	09/14/93	Unger <i>et al.</i>			
	AN	5,385,148	01/31/95	Lesh <i>et al.</i>			
	AO	5,419,777	05/30/95	Hofling			
	AP	5,489,575	02/06/96	Lee <i>et al.</i>			
	AQ	5,499,971	03/19/96	Shapland <i>et al.</i>			
	AR	5,507,724	04/16/96	Hofmann <i>et al.</i>			
	AS	5,569,160	10/29/96	Sauer <i>et al.</i>			
	AT	5,569,217	10/29/96	Luther			
	AU	5,571,215	11/05/96	Sterman <i>et al.</i>			
	AV	5,591,195	01/07/97	Taheri <i>et al.</i>			
	AW	5,653,684	08/05/97	Laptewicz <i>et al.</i>			
	AX	5,661,133	08/26/97	Leiden <i>et al.</i>			
	AY	5,662,124	09/02/97	Wilk			
	AZ	5,693,029	12/02/97	Leonhardt			
	BA	5,698,531	12/16/97	Nabel <i>et al.</i>			
	BB	5,733,250		Withdrawn			
	BC	5,733,280	03/31/98	Avitall			
	BD	5,797,870	08/25/98	March <i>et al.</i>			
	BE	5,797,960	08/25/98	Stevens <i>et al.</i>			
	BF	5,820,592	10/13/98	Hammerslag			
	BG	5,827,216	10/27/98	Igo <i>et al.</i>			
	BH	5,830,993	11/03/98	Blecha <i>et al.</i>			
cm	BI	5,833,658	11/10/98	Levy <i>et al.</i>			

RECEIVED

DEC 29 2003

TECHNOLOGY CENTER R3700



FEB 28 2003

Sheet 2 of 4

TECH CENTER 1000 EXPRESS MAIL NO.: EL 500 578 150 US

		5,840,031	11/24/98	Crowley					
	BK	5,840,059	11/24/98	March <i>et al.</i>					
	BL	5,840,062	11/24/98	Gumaste <i>et al.</i>					
	BM	5,843,050	12/01/98	Jones <i>et al.</i>					
	BN	5,846,221	12/08/98	Snoke <i>et al.</i>					
	BO	5,857,464	01/12/99	Desai					
	BP	5,860,953	01/19/99	Snoke <i>et al.</i>					
	BQ	5,871,495	02/16/99	Mueller					
	BR	5,876,373	03/02/99	Giba <i>et al.</i>					
	BS	5,882,332	03/16/99	Wijay					
	BT	5,885,272	03/23/99	Aita <i>et al.</i>					
	BU	5,891,133	04/06/99	Murphy-Chutorian					
	BV	5,931,831	08/03/99	Linder					
	BW	5,935,063	08/10/99	Nguyen					
	BX	5,941,845	08/24/99	Tu <i>et al.</i>					
	BY	5,941,868	08/24/99	Kaplan <i>et al.</i>					
	BZ	5,964,754	10/12/99	Osypka					
	CA	5,971,983	10/26/99	Lesh					
	CB	5,993,443	11/30/99	Murphy-Chutorian <i>et al.</i>					
	CC	5,997,525	12/07/99	March <i>et al.</i>					
	CD	6,004,269	12/21/99	Crowley <i>et al.</i>					
	CE	6,012,457	01/11/00	Lesh					
	CF	6,024,703	02/15/00	Zanelli <i>et al.</i>					
	CG	6,063,022	05/16/00	Ben-Haim					
	CH	6,133,233	10/17/00	Ross <i>et al.</i>					
	CI	6,183,444	02/06/01	Glines <i>et al.</i>					
	CJ	6,161,543	12/19/00	Cox <i>et al.</i>					
	CK	6,171,303	01/09/01	Ben-Haim <i>et al.</i>					
	CL	6,179,809	01/30/01	Khairkahan <i>et al.</i>					
	CM	6,224,584 B1	05/01/01	March <i>et al.</i>					
	CN	6,237,605 B1	05/29/01	Vaska <i>et al.</i>					
	CO	6,309,375	10/30/01	Glines <i>et al.</i>					
	CP	6,314,962 B1	11/13/01	Vaska <i>et al.</i>					
Ch	CQ	6,314,963 B1	11/13/01	Vaska <i>et al.</i>					

RECEIVED

DEC 29 2003

TECHNOLOGY CENTER R3700

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
Ch	CR	WO 96/32129	10/17/96	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	CS	WO 97/25101	07/17/97	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	CT	WO 97/47253	12/18/97	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	CU	WO 99/39624	08/12/99	PCT			<input type="checkbox"/>	<input type="checkbox"/>
Ch	CV	WO 00/57895	10/05/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>

# OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CW	Padua <i>et al.</i> , "Basic fibroblast growth factor is cardioprotective in ischemia-reperfusion injury" <i>Molecular and Cellular Biochemistry</i> 143: 129-135 (1995)
CX	Shi <i>et al.</i> , "PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47phox" <i>Proc. Natl. Acad. Sci.</i> 93:6014-6018 (1996)
CY	Uchida <i>et al.</i> , "Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: An experimental study" <i>Am. Heart J.</i> , 130:1182-1188 (1995)
CZ	Unger <i>et al.</i> , "Basic fibroblast growth factor enhances myocardial collateral flow in a canine model" <i>Am J. Physiol.</i> , 266:H1577-H1595 (1994)
DA	Walterberger <i>et al.</i> , "Ischemia-Induced Transplant Arteriosclerosis in the Rat" <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> 16(12):1516-1523 (1996)
DB	Xiaobing, <i>et al.</i> , "Ischemia and Reperfusion reduce the Endogenous Basic Fibroblast Growth Factor (bf GF) in Rat Skeletal Muscles" <i>Chinese Medical Journal</i> 108(9): 699-703, (1995)

EXAMINER

DATE CONSIDERED

8/25/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

APPLICATION NO

APPLICANT

FILING DATE

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CW	DC	60/191,610	03/23/00	Tom			
	DD	3,797,491	03/19/74	Hurschman			
	DE	4,222,380	09/16/80	Terayama			
	DF	4,243,035	01/06/81	Barrett			
	DG	4,578,061	03/25/86	Lemelson			
	DH	5,034,003	07/23/91	Denance			
	DI	5,106,370	04/21/92	Stewart			
	DJ	5,322,511	06/21/94	Armbruster <i>et al.</i>			
	DK	5,380,279	01/10/95	Schmidt			
	DL	5,492,119	02/20/96	Abrams			
	DM	5,846,225	12/08/98	Rosengart <i>et al.</i>			
	DN	5,865,811	02/02/99	Doying, Sr. <i>et al.</i>			
	DO	5,951,516	09/14/99	Bunyan			
	DP	5,997,509	12/07/99	Rosengart <i>et al.</i>			
	DQ	6,004,295	12/21/99	Langer <i>et al.</i>			
CW	DR	US 2001/0034501	10/25/01	Tom			


RECEIVED

DEC 29 2003

TECHNOLOGY CENTER R3700

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
--	-----------------	------	---------	-------	----------	-------------



RECEIVED

Sheet 4 of 4

FEB 28 2003

EXPRESS MAIL NO.: EL 500 578 150 US

	WO 98/05307	02/12/98								
DT	WO 99/44656	09/10/99	TECH CENTER 1600/2900							
DU	WO 99/49926	10/07/99								
DV	WO 00/18462	04/06/00								
DW	WO 00/56224	09/28/00								

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

DX	Chu V et al., Angiogenic Response Induced by Mechanical Transmyocardial Revascularization, J. Thorac Cardiovasc Surg Nov; 118(5):849-56 (1999)
DY	Deckelbaum. L.I., Cardiovascular Applications of Laser Technology, Lasers in Surgery and Medicine 15:315-341 (1994)
DZ	Frazier, O.H., Myocardial Revascularization with Laser - Preliminary Findings, Circulation, 1995; 92 [suppl II;II-58-II-65]
EA	Kipshidze et al., Therapeutic Angiogenesis in Patients with Advanced Coronary Artery Disease: Hype or Hope?, J Invas Cardiol 11 (10):589-599 (1999)
EB	Hughes GC et al., Neovascularization After Transmyocardial Laser Recascularization in a Model of Chronic Ischemia, Ann Thorac Surg Dec;66(6):2029-36 (1998)
EC	Prentice H et al., Ischemic/Reperfused Myocardium Can Expresss Recombinant Protein Following Direct DNA or Retroviral Injection, J Mol Cell Cardiol Jan;28(1): 133-40 (1996)
ED	Sayeed-Shah U et al., Complete Reversal of Ischemic Wall Motion Abnormalities by Combined Use of Gene Therapy with Transmyocardial Lasar Revascularization, J Thorac Cardiovasc Surg Nov;116(5):763-9 (1998)
EE	Spanier T et al., Angiogenesis: A Possible Mechanism Underlying the Clinical Benefits of Transmyocardial Laser Revascularization, J Clin Laser Med Surg Dec;15(6):269-73 (1997)
EF	Yamamoto N et al., Angiogenesis is Enhanced in Ischemic Canine Myocardium by Transmyocardial Laser Revascularization, J Am Coll Cardiol May;31(6):1426-33 (1998)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

DEC 29 2003

TECHNOLOGY CENTER R3700